Effects of statins on serum inflammatory markers: The U.S. national health and nutrition examination survey 1999-2004

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 11, 2010, Pages 1176-1182

  Yoon, Sung Sug ^a   Dillon, Charles F ^a   Carroll, Margaret ^a   Llloh, Kachi ^b   Ostchega, Yechiam ^a  

^a NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

C reactive protein (CRP); Ferritin; Inflammation; Statins; White blood cell count (WBC)

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; ETHNICITY; FEMALE; HEALTH SURVEY; HUMAN; INFLAMMATION; INTERVIEW; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; QUESTIONNAIRE; UNITED STATES;

EID: 78649862330     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.5652     Document Type: Article

References (33)

1. Danesh, J, Wheeler JG, Hirschfield GM, Eda S, Eiriks-dottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004; 350: 1387-1397
2. Stewart RA, White HD, Kirby AC, Heritier SR, Simes RJ, Nestel PJ, West MJ, Colquhoun DM, Tonkin AM: White blood cell count predicts reduction in coronary heart disease mortality with Pravastatin. Circulation, 2005; 111: 1756-1762
3. Mora S, Rifai N, Buring JE, Ridker PM: Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation, 2006; 114: 381-387
4. Wilson PW, Nam BH, Pencina MD, Agostino RB, Benjamin EJ, O'Donnell CJ: C-reactive protein and risk of cardiovascular disease in men and women from the Framing-ham Heart Study. Arch Intern Med, 2005; 165: 2473-2478
5. Sung KC, Kang JH, Shin HS: Relationship of cardiovascular risk factors and serum Ferritin with C-reactive protein. Arch Med Res, 2007; 38: 121-125
6. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J: HMG-CoA reductase inhibition by Atorvastatin reduces neointi-mal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998; 32: 2057-2064
7. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMG-CoA reductase inhibitor, Cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001; 103: 276-283
8. Rosenson RS, Tangney CC: Antiatherothrombotic properties of Statins: implications for cardiovascular event reduction. JAMA, 1998; 279: 1643-1650
9. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet, 2001; 357: 1063-1068
10. Stenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1-year survival. JAMA, 2001;285:430-436
11. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikcioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ: Effects of early treatment with Statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA, 2006; 295: 2046-2056
12. Hulten E, Jackson JL, Douglas K, George S, Villines TC: The effect of early, intensive Statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med, 2006; 166: 1814-1821
13. Sukhova G, Williams JK, Libby P: Statins reduce inflammation in atheroma of on human primates independent of effects on serum cholesterol. Arterioscler Thromb Vase Biol, 2002; 22: 1452-1458
14. Albert MA, Danielson E, Rifai N, Ridker P MPRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the Pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001;286:64-70
15. Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R: Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J, 2005; 149:451-457
16. National Center for Health Statistics: National Health and Nutrition Examination Survey: NHANES 1999-2000 data files: data, docs, codebooks, SAS code. Available at: http:// www.cdc.gov/nchs/nhanes.htm Accessed July 1, 2009
17. National Heart, Lung and Blood Institute. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 Express). National High Blood Pressure Education Program NIH publication; 2003. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/ express.pdf Accessed, September 24, 2009
18. Klein RJ, Schoenborn C: Age Adjustment Using the 2000 Projected U.S. Population. In: Healthy People 2010 Statistical Notes. Centers for Disease Control and Prevention/National Center for Health Statistics, 2001; 1-10
19. Burtis CA, Ashwood ER, Burns DE: TIETZ Textbook of Clinical Chemistry and Molecular Diagnostics. STLouis, Elsevier Sanuders. Fourth Edition, 56 (2269)
20. Laufs U, Custodis F, Bohm M: HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs, 2006; 66: 145-154
21. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A: Non-lipid-related effects of Statins. Ann Med, 2000; 32: 164-176
22. Stancu C, Sima A: Statins: mechanism of action and effects. J Cell Mol Med, 2001; 5: 378-387
23. Ridker PM: C-reactive protein and risks of future myocar- dial infarction and thrombotic stroke. Eur Heart J, 1998; 19: 1-3
24. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of Pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1999; 100: 230-235
25. Libby P: Extending knowledge of the benefits of Statins: The Heart Protection Study. Curr Atheroscler Rep, 2002; 4:211-212
26. Jialal I, Devaraj S: Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol, 2001; 116 Suppl: S108-115
27. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT Glynn RJ; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207
28. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation, 2009; 120:2188-2196
29. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sal-lis JF Jr, Smith S Jr, Stone NJ, Taubert KA: American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation, 2003; 107:645-651
30. Williams MJ, Poulton R, Williams S: Relationship of serum Ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis, 2002; 165: 179-184
31. Ostchega Y, Yoon SS, Hughes J, Louis T: Hypertension Awareness, Treatment, and Control - Continued Disparities in US Adults, 2005-06. http://www.cdc.gov/nchs/about/major/nhanes/whatsnew.htm Accessed date: May 23. 2008
32. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH: Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vase Biol, 1997; 17: 2167-2176
33. Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, Brownlee M, Scherer PE: The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem, 2005; 280: 4617-4626